Wisconsin Clinical Trials Report — June 2026

For Wisconsinites considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 75 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 11 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers and hematologic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (5 trials)
• Prostate cancer (2 trials)
• Acute myeloid leukemia (AML) (2 trials)
• Hematologic tests (2 trials)
• Leukemia, myeloid, acute (2 trials)
• Ovarian cancer (2 trials)
• Endometrial cancer (2 trials)
• HER2-negative breast cancer (2 trials)
• Advanced solid tumor (2 trials)

Groundbreaking Research Arrives This Month

This month, Wisconsin welcomes 19 new clinical trials, a notable increase from the 15 trials that opened in May 2026. These new studies include several significant Phase 2 and 3 drug trials from major sponsors, offering participants access to cutting-edge treatments for widespread health challenges like migraine and obesity, as well as crucial initiatives for acute kidney injury and Down syndrome.

• Kallyope Inc. is sponsoring two important Phase 3 trials for migraine treatment. NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized, multicenter evaluation of elismetrep compared to placebo, aiming for 1,800 participants. A companion study, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will further evaluate the long-term safety and tolerability of intermittent use of elismetrep, targeting 1,000 participants.
• For individuals living with obesity or overweight, Boehringer Ingelheim is sponsoring NCT07662122, a Phase 2 "Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight." This trial is open to adults aged 18 to 74 with a BMI of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more with at least one weight-related health problem, and plans for 300 participants.
• Mayo Clinic is leading NCT07670520, "Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial." This large study, aiming for 2,260 participants, seeks to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.
• The RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term study will follow people with Down syndrome of all ages to better understand their health, development, and everyday experiences over time, with a goal of 1,400 participants.
• In the area of public health, Montefiore Medical Center is sponsoring NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study, with 512 participants, is testing whether offering buprenorphine treatment directly at syringe service programs helps more people start and stay in treatment for opioid use disorder.
• The University of Wisconsin, Madison is sponsoring NCT07630428, "Testing STAR and TextSTAR: A Randomized Controlled Trial," which aims to learn if a video and/or a 3-week text messaging intervention can reduce mental health problems and substance misuse following sexual assault, involving 394 participants.
• For men with localized prostate cancer, PROCEPT BioRobotics is sponsoring NCT07650448, "WATER IV PCa (AS Sub-study)." This multicenter, prospective, randomized clinical trial plans for 333 participants to evaluate the safety and efficacy of Aquablation therapy.

New Research Opportunities Across Conditions and Interventions

The 19 new trials opening this month in Wisconsin cover a diverse range of health conditions. The most common conditions addressed by these new studies include:

• Acute kidney injury (1 trial)
• Acute migraine (1 trial)
• Adolescent behavior (1 trial)
• Asthma (1 trial)
• Breast cancer (1 trial)
• Breast carcinoma (1 trial)
• Chromosome disorders (1 trial)
• Down syndrome (1 trial)
• Drug overdose (1 trial)

In terms of intervention types, "Other" research leads the way with 7 new studies, followed by Device (6), Drug (6), Behavioral (5), and Combination Product (1) trials.

Expanding Access Across the Badger State

Wisconsin's clinical research landscape continues to be robust, with 1,210 clinical trials currently recruiting across 85 cities and 648 research sites statewide. This month, the majority of new research initiatives are concentrated in major metropolitan areas, but opportunities are also expanding in other parts of the state:

• Madison (10 new trials)
• Milwaukee (3 new trials)
• Eau Claire (2 new trials)
• Kenosha (2 new trials)
• Sheboygan (1 new trial)
• Wauwatosa (1 new trial)

This distribution ensures that residents in various regions of Wisconsin have access to cutting-edge research, even as Madison remains a central hub for clinical investigations.

Opportunities for Every Wisconsinite

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 19 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 138 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Wisconsin are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include children as participants, and 15 include older adults, ensuring that research benefits diverse age groups. 2 new trials are female-only, and 1 is male-only. Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Wisconsin, Madison sponsoring 7 of the new trials. Other key sponsors include Mayo Clinic (2 trials), Medical College of Wisconsin (2 trials), and industry leaders like Kallyope Inc. (2 trials) and Boehringer Ingelheim (1 trial).

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Wisconsin, with an eye towards the 3 new trials anticipated to open in July.